Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.

Finkelstein JS, Leder BZ, Burnett SM, Wyland JJ, Lee H, de la Paz AV, Gibson K, Neer RM

The Journal of clinical endocrinology and metabolism9 May 2006Cited by 90 (Europe PMC)

PMID16684825DOI10.1210/jc.2006-0190PepBankPUB-16684825

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In osteoporotic men receiving teriparatide alone, serum N-telopeptide rose initially and then declined toward baseline.
In plain wordsIn men with osteoporosis, teriparatide alone first increased serum N-telopeptide, which later declined toward baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedSerum N-telopeptide trajectory with monotherapy
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
37 microg daily · sc · begun at month 6 of a 30-month studyAs given in this study (human).
Source sentences
Summary
In men receiving teriparatide monotherapy (group 2), levels of all bone turnover markers increased markedly during the first 6 months of teriparatide administration and then declined toward baseline during the next 18 months.
5 context sentences(design, population, supporting numbers)
Summary · context
This was a nonblinded, randomized, controlled trial.
Summary · context
We studied 63 men, age 46-85, with low spine and/or hip BMD.
Summary · context
Subjects received alendronate 10 mg daily (group 1), teriparatide 37 microg sc daily (group 2), or both (group 3) for 30 months.
Summary · context
Teriparatide was begun at month 6.
Summary · context
The primary endpoint was the change in serum N-telopeptide, osteocalcin, and amino-terminal propeptide of type 1 procollagen.
Report a problemFND-1668482501
02HumanRandomized controlled trialEfficacy outcome
In osteoporotic men receiving teriparatide alone, osteocalcin rose initially and then declined toward baseline.
In plain wordsIn men with osteoporosis, teriparatide alone first increased osteocalcin, which later declined toward baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedOsteocalcin trajectory with monotherapy
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
37 microg daily · sc · begun at month 6 of a 30-month studyAs given in this study (human).
Source sentences
Summary
In men receiving teriparatide monotherapy (group 2), levels of all bone turnover markers increased markedly during the first 6 months of teriparatide administration and then declined toward baseline during the next 18 months.
5 context sentences(design, population, supporting numbers)
Summary · context
This was a nonblinded, randomized, controlled trial.
Summary · context
We studied 63 men, age 46-85, with low spine and/or hip BMD.
Summary · context
Subjects received alendronate 10 mg daily (group 1), teriparatide 37 microg sc daily (group 2), or both (group 3) for 30 months.
Summary · context
Teriparatide was begun at month 6.
Summary · context
The primary endpoint was the change in serum N-telopeptide, osteocalcin, and amino-terminal propeptide of type 1 procollagen.
Report a problemFND-1668482502
03HumanRandomized controlled trialEfficacy outcome
In osteoporotic men receiving teriparatide alone, procollagen type 1 amino-terminal propeptide rose initially and then declined toward baseline.
In plain wordsIn men with osteoporosis, teriparatide alone first increased a procollagen marker, which later declined toward baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedProcollagen type 1 amino-terminal propeptide trajectory with monotherapy
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
37 microg daily · sc · begun at month 6 of a 30-month studyAs given in this study (human).
Source sentences
Summary
In men receiving teriparatide monotherapy (group 2), levels of all bone turnover markers increased markedly during the first 6 months of teriparatide administration and then declined toward baseline during the next 18 months.
5 context sentences(design, population, supporting numbers)
Summary · context
This was a nonblinded, randomized, controlled trial.
Summary · context
We studied 63 men, age 46-85, with low spine and/or hip BMD.
Summary · context
Subjects received alendronate 10 mg daily (group 1), teriparatide 37 microg sc daily (group 2), or both (group 3) for 30 months.
Summary · context
Teriparatide was begun at month 6.
Summary · context
The primary endpoint was the change in serum N-telopeptide, osteocalcin, and amino-terminal propeptide of type 1 procollagen.
Report a problemFND-1668482503
04HumanRandomized controlled trialEfficacy outcome
In osteoporotic men, N-telopeptide changes differed significantly between teriparatide monotherapy and alendronate monotherapy.
In plain wordsIn men with osteoporosis, N-telopeptide changes differed between teriparatide alone and alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedN-telopeptide change versus alendronate
Study
n: not reported in source
Comparator
Alendronate alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
37 microg daily · sc · begun at month 6 of a 30-month studyAs given in this study (human).
Measurements
P value
< 0.001 NA
groups 1 and 2
Source sentences
Summary
Changes in each marker were significantly different between groups 1 and 2 (all P values < 0.001), groups 1 and 3 (all P values < 0.001), and groups 2 and 3 (all P values < 0.03).
5 context sentences(design, population, supporting numbers)
Summary · context
This was a nonblinded, randomized, controlled trial.
Summary · context
We studied 63 men, age 46-85, with low spine and/or hip BMD.
Summary · context
Subjects received alendronate 10 mg daily (group 1), teriparatide 37 microg sc daily (group 2), or both (group 3) for 30 months.
Summary · context
Teriparatide was begun at month 6.
Summary · context
The primary endpoint was the change in serum N-telopeptide, osteocalcin, and amino-terminal propeptide of type 1 procollagen.
Report a problemFND-1668482507
05HumanRandomized controlled trialEfficacy outcome
In osteoporotic men, osteocalcin changes differed significantly between teriparatide monotherapy and alendronate monotherapy.
In plain wordsIn men with osteoporosis, osteocalcin changes differed between teriparatide alone and alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedOsteocalcin change versus alendronate
Study
n: not reported in source
Comparator
Alendronate alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
37 microg daily · sc · begun at month 6 of a 30-month studyAs given in this study (human).
Measurements
P value
< 0.001 NA
groups 1 and 2
Source sentences
Summary
Changes in each marker were significantly different between groups 1 and 2 (all P values < 0.001), groups 1 and 3 (all P values < 0.001), and groups 2 and 3 (all P values < 0.03).
5 context sentences(design, population, supporting numbers)
Summary · context
This was a nonblinded, randomized, controlled trial.
Summary · context
We studied 63 men, age 46-85, with low spine and/or hip BMD.
Summary · context
Subjects received alendronate 10 mg daily (group 1), teriparatide 37 microg sc daily (group 2), or both (group 3) for 30 months.
Summary · context
Teriparatide was begun at month 6.
Summary · context
The primary endpoint was the change in serum N-telopeptide, osteocalcin, and amino-terminal propeptide of type 1 procollagen.
Report a problemFND-1668482508
06HumanRandomized controlled trialEfficacy outcome
In osteoporotic men, procollagen type 1 amino-terminal propeptide changes differed significantly between teriparatide alone and alendronate alone.
In plain wordsIn men with osteoporosis, procollagen marker changes differed between teriparatide alone and alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedProcollagen propeptide change versus alendronate
Study
n: not reported in source
Comparator
Alendronate alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
37 microg daily · sc · begun at month 6 of a 30-month studyAs given in this study (human).
Measurements
P value
< 0.001 NA
groups 1 and 2
Source sentences
Summary
Changes in each marker were significantly different between groups 1 and 2 (all P values < 0.001), groups 1 and 3 (all P values < 0.001), and groups 2 and 3 (all P values < 0.03).
5 context sentences(design, population, supporting numbers)
Summary · context
This was a nonblinded, randomized, controlled trial.
Summary · context
We studied 63 men, age 46-85, with low spine and/or hip BMD.
Summary · context
Subjects received alendronate 10 mg daily (group 1), teriparatide 37 microg sc daily (group 2), or both (group 3) for 30 months.
Summary · context
Teriparatide was begun at month 6.
Summary · context
The primary endpoint was the change in serum N-telopeptide, osteocalcin, and amino-terminal propeptide of type 1 procollagen.
Report a problemFND-1668482509
07HumanRandomized controlled trialEfficacy outcome
In osteoporotic men, N-telopeptide changes differed significantly between teriparatide plus alendronate and alendronate alone.
In plain wordsIn men with osteoporosis, N-telopeptide changes differed between teriparatide plus alendronate and alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedN-telopeptide change with addition to alendronate
Study
n: not reported in source
Comparator
Alendronate alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
37 microg daily · sc · begun at month 6 of a 30-month studyAs given in this study (human).
Measurements
P value
< 0.001 NA
groups 1 and 3
Source sentences
Summary
Changes in each marker were significantly different between groups 1 and 2 (all P values < 0.001), groups 1 and 3 (all P values < 0.001), and groups 2 and 3 (all P values < 0.03).
5 context sentences(design, population, supporting numbers)
Summary · context
This was a nonblinded, randomized, controlled trial.
Summary · context
We studied 63 men, age 46-85, with low spine and/or hip BMD.
Summary · context
Subjects received alendronate 10 mg daily (group 1), teriparatide 37 microg sc daily (group 2), or both (group 3) for 30 months.
Summary · context
Teriparatide was begun at month 6.
Summary · context
The primary endpoint was the change in serum N-telopeptide, osteocalcin, and amino-terminal propeptide of type 1 procollagen.
Report a problemFND-1668482510
08HumanRandomized controlled trialEfficacy outcome
In osteoporotic men, osteocalcin changes differed significantly between teriparatide plus alendronate and alendronate alone.
In plain wordsIn men with osteoporosis, osteocalcin changes differed between teriparatide plus alendronate and alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedOsteocalcin change with addition to alendronate
Study
n: not reported in source
Comparator
Alendronate alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
37 microg daily · sc · begun at month 6 of a 30-month studyAs given in this study (human).
Measurements
P value
< 0.001 NA
groups 1 and 3
Source sentences
Summary
Changes in each marker were significantly different between groups 1 and 2 (all P values < 0.001), groups 1 and 3 (all P values < 0.001), and groups 2 and 3 (all P values < 0.03).
5 context sentences(design, population, supporting numbers)
Summary · context
This was a nonblinded, randomized, controlled trial.
Summary · context
We studied 63 men, age 46-85, with low spine and/or hip BMD.
Summary · context
Subjects received alendronate 10 mg daily (group 1), teriparatide 37 microg sc daily (group 2), or both (group 3) for 30 months.
Summary · context
Teriparatide was begun at month 6.
Summary · context
The primary endpoint was the change in serum N-telopeptide, osteocalcin, and amino-terminal propeptide of type 1 procollagen.
Report a problemFND-1668482511
09HumanRandomized controlled trialEfficacy outcome
In osteoporotic men, procollagen type 1 amino-terminal propeptide changes differed significantly between teriparatide plus alendronate and alendronate alone.
In plain wordsIn men with osteoporosis, procollagen marker changes differed between teriparatide plus alendronate and alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedProcollagen propeptide change with addition to alendronate
Study
n: not reported in source
Comparator
Alendronate alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
37 microg daily · sc · begun at month 6 of a 30-month studyAs given in this study (human).
Measurements
P value
< 0.001 NA
groups 1 and 3
Source sentences
Summary
Changes in each marker were significantly different between groups 1 and 2 (all P values < 0.001), groups 1 and 3 (all P values < 0.001), and groups 2 and 3 (all P values < 0.03).
5 context sentences(design, population, supporting numbers)
Summary · context
This was a nonblinded, randomized, controlled trial.
Summary · context
We studied 63 men, age 46-85, with low spine and/or hip BMD.
Summary · context
Subjects received alendronate 10 mg daily (group 1), teriparatide 37 microg sc daily (group 2), or both (group 3) for 30 months.
Summary · context
Teriparatide was begun at month 6.
Summary · context
The primary endpoint was the change in serum N-telopeptide, osteocalcin, and amino-terminal propeptide of type 1 procollagen.
Report a problemFND-1668482512

Studies that did not test the peptide alone6

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In osteoporotic men, N-telopeptide returned to baseline after teriparatide joined alendronate, following an initial decline during alendronate alone.
In plain wordsIn men with osteoporosis, N-telopeptide returned to baseline after teriparatide joined alendronate, following a decline during alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedSerum N-telopeptide after combination therapy
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In men who received combination therapy (group 3), bone turnover marker levels declined in the first 6 months (while receiving alendronate alone) and then returned to baseline levels (N-telopeptide) or above (osteocalcin and amino-terminal propeptide of type 1 procollagen) after teriparatide was added.
5 context sentences(design, population, supporting numbers)
Summary · context
This was a nonblinded, randomized, controlled trial.
Summary · context
We studied 63 men, age 46-85, with low spine and/or hip BMD.
Summary · context
Subjects received alendronate 10 mg daily (group 1), teriparatide 37 microg sc daily (group 2), or both (group 3) for 30 months.
Summary · context
Teriparatide was begun at month 6.
Summary · context
The primary endpoint was the change in serum N-telopeptide, osteocalcin, and amino-terminal propeptide of type 1 procollagen.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1668482504
11HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In osteoporotic men, osteocalcin rose above baseline after teriparatide joined alendronate, following an initial decline during alendronate alone.
In plain wordsIn men with osteoporosis, osteocalcin rose above baseline after teriparatide joined alendronate, following a decline during alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOsteocalcin after combination therapy
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In men who received combination therapy (group 3), bone turnover marker levels declined in the first 6 months (while receiving alendronate alone) and then returned to baseline levels (N-telopeptide) or above (osteocalcin and amino-terminal propeptide of type 1 procollagen) after teriparatide was added.
5 context sentences(design, population, supporting numbers)
Summary · context
This was a nonblinded, randomized, controlled trial.
Summary · context
We studied 63 men, age 46-85, with low spine and/or hip BMD.
Summary · context
Subjects received alendronate 10 mg daily (group 1), teriparatide 37 microg sc daily (group 2), or both (group 3) for 30 months.
Summary · context
Teriparatide was begun at month 6.
Summary · context
The primary endpoint was the change in serum N-telopeptide, osteocalcin, and amino-terminal propeptide of type 1 procollagen.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1668482505
12HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In osteoporotic men, procollagen type 1 amino-terminal propeptide rose above baseline after teriparatide joined alendronate.
In plain wordsIn men with osteoporosis, a procollagen marker rose above baseline after teriparatide joined alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseProcollagen type 1 amino-terminal propeptide after combination therapy
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In men who received combination therapy (group 3), bone turnover marker levels declined in the first 6 months (while receiving alendronate alone) and then returned to baseline levels (N-telopeptide) or above (osteocalcin and amino-terminal propeptide of type 1 procollagen) after teriparatide was added.
5 context sentences(design, population, supporting numbers)
Summary · context
This was a nonblinded, randomized, controlled trial.
Summary · context
We studied 63 men, age 46-85, with low spine and/or hip BMD.
Summary · context
Subjects received alendronate 10 mg daily (group 1), teriparatide 37 microg sc daily (group 2), or both (group 3) for 30 months.
Summary · context
Teriparatide was begun at month 6.
Summary · context
The primary endpoint was the change in serum N-telopeptide, osteocalcin, and amino-terminal propeptide of type 1 procollagen.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1668482506
13HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In osteoporotic men, N-telopeptide changes differed significantly between teriparatide plus alendronate and teriparatide alone.
In plain wordsIn men with osteoporosis, N-telopeptide changes differed between teriparatide plus alendronate and teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedN-telopeptide change with combination versus teriparatide
Study
n: not reported in source
Comparator
Teriparatide alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Measurements
P value
< 0.03 NA
groups 2 and 3
Source sentences
Summary
Changes in each marker were significantly different between groups 1 and 2 (all P values < 0.001), groups 1 and 3 (all P values < 0.001), and groups 2 and 3 (all P values < 0.03).
5 context sentences(design, population, supporting numbers)
Summary · context
This was a nonblinded, randomized, controlled trial.
Summary · context
We studied 63 men, age 46-85, with low spine and/or hip BMD.
Summary · context
Subjects received alendronate 10 mg daily (group 1), teriparatide 37 microg sc daily (group 2), or both (group 3) for 30 months.
Summary · context
Teriparatide was begun at month 6.
Summary · context
The primary endpoint was the change in serum N-telopeptide, osteocalcin, and amino-terminal propeptide of type 1 procollagen.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1668482513
14HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In osteoporotic men, osteocalcin changes differed significantly between teriparatide plus alendronate and teriparatide alone.
In plain wordsIn men with osteoporosis, osteocalcin changes differed between teriparatide plus alendronate and teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedOsteocalcin change with combination versus teriparatide
Study
n: not reported in source
Comparator
Teriparatide alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Measurements
P value
< 0.03 NA
groups 2 and 3
Source sentences
Summary
Changes in each marker were significantly different between groups 1 and 2 (all P values < 0.001), groups 1 and 3 (all P values < 0.001), and groups 2 and 3 (all P values < 0.03).
5 context sentences(design, population, supporting numbers)
Summary · context
This was a nonblinded, randomized, controlled trial.
Summary · context
We studied 63 men, age 46-85, with low spine and/or hip BMD.
Summary · context
Subjects received alendronate 10 mg daily (group 1), teriparatide 37 microg sc daily (group 2), or both (group 3) for 30 months.
Summary · context
Teriparatide was begun at month 6.
Summary · context
The primary endpoint was the change in serum N-telopeptide, osteocalcin, and amino-terminal propeptide of type 1 procollagen.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1668482514
15HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In osteoporotic men, procollagen type 1 amino-terminal propeptide changes differed significantly between teriparatide plus alendronate and teriparatide alone.
In plain wordsIn men with osteoporosis, procollagen marker changes differed between teriparatide plus alendronate and teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedProcollagen propeptide change with combination versus teriparatide
Study
n: not reported in source
Comparator
Teriparatide alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Measurements
P value
< 0.03 NA
groups 2 and 3
Source sentences
Summary
Changes in each marker were significantly different between groups 1 and 2 (all P values < 0.001), groups 1 and 3 (all P values < 0.001), and groups 2 and 3 (all P values < 0.03).
5 context sentences(design, population, supporting numbers)
Summary · context
This was a nonblinded, randomized, controlled trial.
Summary · context
We studied 63 men, age 46-85, with low spine and/or hip BMD.
Summary · context
Subjects received alendronate 10 mg daily (group 1), teriparatide 37 microg sc daily (group 2), or both (group 3) for 30 months.
Summary · context
Teriparatide was begun at month 6.
Summary · context
The primary endpoint was the change in serum N-telopeptide, osteocalcin, and amino-terminal propeptide of type 1 procollagen.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1668482515

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.